Navigation Links
New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
Date:11/7/2011

ely to severely active rheumatoid arthritis. Cimzia® in combination with MTX, is approved in the EU for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying antirheumatic drugs (DMARDs) including MTX. Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

For further information on UCB products, please visit www.UCB.com.

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

IMPORTANT SAFETY INFORMATION

Risk of Serious Infections and Malignancy

Patients treated with CIMZIA are at a
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... technologies are used to develop, manufacture and sell enzymes ... and industrial enzyme industries, announced today that it will ... June 30, 2014 after market close on Thursday, August ... day at 5:00 p.m. Eastern Time to discuss those ...
(Date:7/31/2014)... 2014  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
(Date:7/31/2014)... RMD ) today announced results for its fourth ... Revenue for the quarter was $415.2 million, flat compared to ... on a constant currency basis). Net income was $87.7 million, ... June 30, 2013. Diluted earnings per share for the quarter ... quarter ended June 30, 2013.  The results ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... Reportlinker.com announces that a new market ... Triple Analysis: Lymphoma, Prostate ... http://www.reportlinker.com/p0284719/Triple-Analysis-Lymphoma-Prostate-Cancer-and-Antibodies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology This triple analysis ... both Lymphoma and Prostate Cancer and by ...
... CYBX ), a global leader in epilepsy management, today ... Conference on Wednesday, June 8, 2011, in New York. ... Financial Officer, will speak to the attendees of the conference ... the presentation can be accessed by clicking on the Investor ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 2Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 3Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 4Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 5
(Date:8/2/2014)... Dr. Ping Hu is a worldly educated and ... from the Capital Medical University in Beijing, China and ... from the University of London. She completed her ... and finished her fellowship at the University of Illinois ... both inside and outside of the classroom with her ...
(Date:8/2/2014)... When the Black Hat conventioneers descend on Las ... thing can be always counted on, plenty of FUD will ... and doubt. The run-up has already made its share ... Reuters on July 31st about how hackers could use ... successfully infect a system with malware, completely undetected, by leveraging ...
(Date:8/1/2014)... 02, 2014 The successful development of ... business of Guangdong FODAY Automobile Co.,LTD. As early as ... had already organized an excellent team to develop a ... detailed, in-depth technical plans. The company’s vice president Liming ... the direct involvement of the specific arrangement and the ...
(Date:8/1/2014)... Cannabis use among young people has spiked, with ... used marijuana at least once and 17 percent admitting to ... Drugs, Say ‘Yes to Life,’ volunteers from the Church of ... with factual information about drugs, to help reverse this alarming ... to Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 ...
(Date:8/1/2014)... the University of California, San Diego School of Medicine ... chili peppers produces chronic activation of a receptor ... reaction that ultimately reduces the risk of colorectal tumors. ... 2014 issue of The Journal of Clinical Investigation ... was originally discovered in sensory neurons, where it acts ...
Breaking Medicine News(10 mins):Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2
... are smokers with implanted defibrillators had seven times higher a ... their heart into normal rhythm than nonsmokers with the device. ... School of Medicine in St. Louis .Eleven percent of cardiovascular ... that decreasing or quitting smoking is in itself a very ...
... A news study appearing in the June 15, 2006 ... Cancer Society, says that external beam radiation// could be ... years diagnosed with prostate cancer. ,Age has ... prostate cancer. In younger individuals, doctors recommend more aggressive ...
... was found that de- addiction drug help to combat alcoholism. ... Naltrexone//. This drug blocks craving for any sort of drug. ... American Medical Association. This drug can be made accessible ... of alcohol addicts. The two drugs that were tested are ...
... been warned against running long distances, as his health seems ... examined him//. ,The kid's clinical parameters such as ... are higher, according to Sugat Kar, Chief medical officer, Capital ... to have high blood pressure (135/85 mm Hg) and a ...
... the Human Fertility and Embryology Authority (HFEA) is evident that there ... a later age. Based on statistics it was seen that in ... or over. But in 2002, 24 babies were born to women ... NHS say that IVF should not be done to women over ...
... (IPF) is a disease whose cause and cure are not ... till date//. It is a lung disease characterized by scarring ... entire organ (lung). Statistics show that approximately 83,000 ... diagnosed every year. Ten years ago Jean Thompson became ...
Cached Medicine News:Health News:Jolt to Quit Smoking 2Health News:Slow Down Budhia, Warn Medical Experts 2Health News:Lesser Know Facts about Idiopathic Pulmonary Fibrosis (IPF) 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: